維妥珠單抗
化合物
維妥珠單抗（INN：veltuzumab；開發代號：IMMU-106[1]）是一種單株抗體（靶向CD20），正在研究用於治療非霍奇金淋巴瘤。[2][3]截至2011年12月[update]，該藥物正在進行I/II期臨床試驗。[4]當與米拉珠單抗一起使用時，它顯示出活性。[5]
| 單株抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | CD20 |
| 臨床資料 | |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 728917-18-8  |
| ChemSpider |
|
| UNII | |
| 化學資訊 | |
| 化學式 | C6458H9918N1706O2026S46 |
| 摩爾質量 | 145,349.06 g·mol−1 |
該藥物由Immunomedics開發。
2015年8月，美國食品藥品監督管理局授予其治療免疫性血小板減少症的孤兒藥地位。[6]II期試驗計劃將持續5年。[6]
參考資料
- ^ Zibelman M, Borghaei H, Olszanski AJ. Harnessing Innate Immunity. Dubel S, Reichert JM (編). Handbook of Therapeutic Antibodies 2nd. John Wiley & Sons. 2014: 791. ISBN 978-3-527-68244-7. doi:10.1002/9783527682423.ch27.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Veltuzumab, American Medical Association.
- ^ Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH. CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood. October 2009, 114 (18): 3864–71. PMC 2773491
. PMID 19710501. doi:10.1182/blood-2009-06-228890.
- ^ Clinical trial number NCT00546793 for "Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL" at ClinicalTrials.gov
- ^ Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, et al. The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. British Journal of Haematology. June 2015, 169 (5): 701–10. PMC 7297055 . PMID 25847298. doi:10.1111/bjh.13354.
- ^ 6.0 6.1 FDA grants orphan drug designation to veltuzumab for ITP. HemOnc Today. Healio.com. August 4, 2015.
